clinical trial – Page 187 – Communicable Diseases Research

Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models

Research Article

Published on 2020-12-102022-10-31
Journal: Emerging Microbes & Infections [Category] COVID-19, SARS,

Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial

성인의 중증 COVID-19 치료를 위한 분무형 계면활성제(COV-Surf): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Randomized Controlled Trial

Published on 2020-12-102022-09-10
Journal: Trials [Category] MERS, SARS, 비임상, 임상,

[키워드] 1080 24 hour 24 hours 48 hour 48 hours ACE2 ADEs administration Adverse adverse event adverse events AEs ALEA All participant All participants allergy alveolar angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 anticipated attending physician bind Blinding block randomization Blood bovine breath buffer calcium cells cellular cholesterol Chronic kidney disease class clinical Clinical improvement clinical trial clinical trials Cohort Combination comparator Compliance Concentration conducted Consent contraindication contributing to Control control arm controls COVID-19 COVID-19 adult patient COVID-19 patients current cytokine Data collection Data monitoring committee death declined defined delivery described Device dialysis discretion dissemination dose drug Effect Efficacy EGFR element Eligible participants end point End-Expiratory Pressure Endotracheal intubation enrolled Enrollment enrolment epithelial Escalation EudraCT evaluate exclusion exclusion criteria expected fatty Fatty acid feasibility free fatty acid Frequency hospital hospitalised hypoxia impair include inclusion criteria index Inflammatory marker inflammatory markers Inflammatory response intensive care intensive care unit Intervention investigator Kidney disease lack liver liver failure Local lung lung lavage mechanical ventilation mechanical ventilator mechanically ventilated patient mechanically ventilated patients mixture Mortality nebulisation number objective Open-label opinion Ordinal Scale other treatment outcome oxidative stress Oxygenation PaO participant Patient PCR PEEP Phosphatidylcholine phosphatidylethanolamine phosphatidylglycerol phosphatidylinositol phospholipid PIP Placebo plasma Pneumothorax Positive end-expiratory pressure Prevent Primary outcome progression Protein protocol pulmonary compliance pulmonary hemorrhage pulmonary ventilation quantification randomisation randomised randomised controlled trial Randomized Randomized controlled trial reached receive recorded recruitment reduction Registered reported Respiratory failure SAEs Sample size SARS-CoV-2 viral load SARS-CoV-2 virus secondary outcome Secondary outcomes Serious Adverse Events severe COVID-19 severity sphingomyelin Stage Standard Standard of care status Study protocol subject supplementary material surface tension surfactant synthesis tension the WHO tissue damage total sample size tracheal tracheal aspirate Tracheal aspirates transfer Treatment Trial Trial Steering Committee turnover unique university University College London usual standard of care Ventilation Ventilation Index ventilatory support VFD vibrating mesh nebulizer Viral Viral load virus water website weight with COVID-19 worsening
[DOI] 10.1186/s13063-020-04944-5 PMC 바로가기 [Article Type] Randomized Controlled Trial

Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases

Article

Published on 2020-12-092022-10-04
Journal: The World Allergy Organization Journal [Category] 임상,

[키워드] ACE, Angiotensin converting enzyme AT₁R, Angiotensin II receptor type 1 BMI, Body mass index Broccoli Broccoli, Broccoli seed capsules Capsule carried clinical benefit clinical trial cough Cough challenge COVID-19 COVID-19 symptoms COVID-19, Coronavirus 19 disease described dose double-blind Effect effective Efficacy and safety help High dose Hypothesis induce less NAPQI, N-acetyl-p-benzoquinone imine nasal Nrf2 Nrf2, Nuclear factor (erythroid-derived 2)-like 2 onset of action onset of symptoms Patient per day Prevent reduce repeated SARS-COV-2 infection SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 SARS, Severe acute respiratory syndrome severe COVID-19 symptoms Symptom the cytokine storm the patient Trial TRP, Transient receptor potential TRPA1 TRPA1, Transient receptor potential ankyrin 1 TRPV1 TRPV1, Transient receptor potential vanillin 1 VAS, Visual analogue scale
[DOI] 10.1016/j.waojou.2020.100498 PMC 바로가기 [Article Type] Article

Rhinacanthus nasutus “Tea” Infusions and the Medicinal Benefits of the Constituent Phytochemicals

Review

Published on 2020-12-092022-10-31
Journal: Nutrients [Category] COVID-19,

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

COVID-19 환자의 숙주 혈전 염증 반응 조절에 대한 무작위, 공개, 적응, 개념 증명 임상 시험: DAWn-Antico 연구

Randomized Controlled Trial

Published on 2020-12-092022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] Activation adaptive added Anakinra Aprotinin bradykinin cellular entry Clinical improvement clinical status clinical trial Coagulation Combination complications Contact country COVID-19 COVID-19 disease COVID-19 pandemic D-dimer defined develop Disease progression dose drug effective EU Clinical Trial EU Clinical Trials fibrinolysis heparin heparins high mortality hospitalized COVID-19 patients Host hyperinflammation ICU in vitro incidence Infection inflammatory parameters Inflammatory response information inhibitor inhibitory effect initial intensive care Intervention investigated Kallikrein local inflammatory response low molecular weight Low molecular weight heparins marker modulate modulation multicenter Open-label Ordinal Scale outcome pathophysiological pathway Patient Primary outcome Prognostic factor proof-of-concept clinical trial Randomized randomized clinical trial reached receptor receptor antagonist reduce regimen SARS-CoV-2 second wave severe COVID-19 severe COVID-19 disease shown standard thromboprophylaxis supplementary material the WHO Thromboinflammatory response thrombotic Thrombotic complications Thrombotic events Trial Trial registration vaccination Viral viral replication WHO ordinal scale
[DOI] 10.1186/s13063-020-04878-y PMC 바로가기 [Article Type] Randomized Controlled Trial

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial

Randomized Controlled Trial

Published on 2020-12-082022-10-05
Journal: JAMA [Category] 임상,

[키워드] absolute difference acute respiratory syndrome adult outpatient adverse events age assigned clinical Clinical deterioration Clinical efficacy clinical trial coronavirus Coronavirus disease 2019 COVID-19 criteria cytokine production decrease defined Deterioration determine enrolled excessive immune response Final fluvoxamine Follow-up greater Hospitalization Infection less likelihood mild COVID-19 illness occurred outcome outcome measures Outpatient oxygen saturation participant Patient patients treated Placebo Pneumonia Prevent Primary outcome randomization Randomized randomized trial Randomly receive receptor regulate Serious Adverse Event Severity of disease Shortness of breath small sample size supplemental oxygen survival symptom onset symptomatic the placebo group Trial with COVID-19 women
[DOI] 10.1001/jama.2020.22760 PMC 바로가기 [Article Type] Randomized Controlled Trial

Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19

Article

Published on 2020-12-072022-10-30
Journal: iScience [Category] COVID-19,

Zinc, Vitamin D and Vitamin C: Perspectives for COVID-19 With a Focus on Physical Tissue Barrier Integrity

Nutrition

Published on 2020-12-072022-10-31
Journal: Frontiers in Nutrition [Category] COVID-19,

Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus

Review

Published on 2020-12-072022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] ACE2 acute respiratory syndrome affected aggravate angiotensin-converting enzyme 2 anti-inflammatory effect Asymptomatic COVID-19 Autoimmune benefit binding caused Cell cleavage clinical trial coronavirus Coronavirus disease 2019 COVID-19 COVID-19 progression cytosolic Diabetes Mellitus Dipeptidyl peptidase-4 Effectiveness Evidence exhibit facilitate furin global pandemic glycemic control glycosylation Hospitalization human Angiotensin-converting enzyme hyperglycemia immune response induce inhibitor Injury innate immune system Innate immunity Lactate lower mortality medication metabolites Mild novel outcomes pancreatic Patient patients with diabete pro-inflammatory cytokine protective effect Randomized receptor reduction in renin–angiotensin–aldosterone system S protein SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome coronavirus 2 susceptibility targets Th1 Th2 immunity the S protein TMPRSS2 transmembrane serine protease Treatment Trigger uncontrolled vicious cycle viral entry viral genome viral S protein
[DOI] 10.3390/jcm9123962 PMC 바로가기 [Article Type] Review

L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies

Short Communication

Published on 2020-12-062022-10-04
Journal: Computational and Structural Biotechnology Journal [Category] 신약개발, 치료제,